Novartis, Eli Lilly and Amgen-backed cancer immunotherapy developer Surface Oncology has filed for a $75m offering on Nasdaq.

Biopharmaceuticals developer Aslan Pharmaceuticals, which counts AMT, Accuron and Tianda as backers, has filed to raise up to $86.3m in an initial public offering.

Alphabet subsidiaries Capital G and Verily Life Sciences took part in a round that took Oscar's total funding to $935m, valuing it at $3.2bn.

Parkwalk has invested from two vehicles under its management after previously backing the Cambridge spinout in late 2016.

Geodesic Capital is raising a supplementary fund that aims to open up the Japanese market for US-based startups, and has secured Hitachi as a limited partner.

The WuXi PharmaTech-backed cancer treatment developer has received $50m in a round featuring another corporate investor, New World TMT.

Total Energy Ventures will invest approximately $48m in the new energy fund as one of its three anchor partners, on the way to a $239m close.

Rakuten and Bloomberg Beta have backed a $10.4m round for Everledger, the developer of a tracing system for precious resources.

Groupe ADP and existing investor Airbus Ventures kicked in funds as the transport management platform boosted its total funding to more than $16m.